- COVID vaccine generated robust immune response in a group of healthy adults
- Oxford vaccine produced a similar immune response among older adults
- Adverse reactions of Oxford COVID-19 were lower among the elderly
London: The COVID-19 vaccine being developed by the University of Oxford produces an immune response in both elderly and young people and adverse reactions were lower among the elderly, British drug maker AstraZeneca Plc said on Monday (October 26). A vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people, hammered the global economy and shuttered normal life across the world. The Financial Times reported that the vaccine, being developed by Oxford and AstraZeneca, triggers protective antibodies and T-cells in older age groups. It cited two people familiar with the finding.
Also Read: COVID-19: Third Phase Human Trial Of Covaxin To Commence At Odisha’s Hospital Soon
Immunogenicity blood tests carried out on a subset of older participants echo data released in July which showed the vaccine generated “robust immune responses” in a group of healthy adults aged between 18 and 55, the newspaper reported.
It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher, an AstraZeneca spokesman told Reuters.
“The results further build the body of evidence for the safety and immunogenicity of AZD1222,” the spokesman said.
Details of the finding are expected to be published shortly in a clinical journal, the FT said. It did not name the publication.
AstraZeneca, which is developing the vaccine with Oxford University researchers, is seen as a frontrunner in the race to produce a vaccine to protect against COVID-19.
British Health Secretary Matt Hancock said a vaccine was not yet ready though he was preparing logistics for a possible roll out. He said he expected the roll out to happen in the first half of 2021.
Also Read: Centre Has Sufficient Financial Resources To Procure 400-500 Million Doses Of COVID-19 Vaccine: Health Ministry
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.